Cargando…

The A to I editing landscape in melanoma and its relation to clinical outcome

RNA editing refers to non-transient RNA modifications that occur after transcription and prior to translation by the ribosomes. RNA editing is more widespread in cancer cells than in non-transformed cells and is associated with tumorigenesis of various cancer tissues. However, RNA editing can also g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amweg, Austeja, Tusup, Marina, Cheng, Phil, Picardi, Ernesto, Dummer, Reinhard, Levesque, Mitchell P, French, Lars E, Guenova, Emmanuella, Läuchli, Severin, Kundig, Thomas, Mellett, Mark, Pascolo, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415457/ https://www.ncbi.nlm.nih.gov/pubmed/35993275 http://dx.doi.org/10.1080/15476286.2022.2110390

Ejemplares similares

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma
por: Tusup, Marina, et al.
Publicado: (2021)

Correction: Tusup et al. Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma. Non-Coding RNA 2021, 7, 5
por: Tusup, Marina, et al.
Publicado: (2022)

Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring
por: Jarzebska, Natalia Teresa, et al.
Publicado: (2021)

mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma
por: Tusup, Marina, et al.
Publicado: (2021)

Functional differences between protamine preparations for the transfection of mRNA
por: Jarzebska, Natalia Teresa, et al.
Publicado: (2020)

Epitranscriptomics of cancer
por: Tusup, Marina, et al.
Publicado: (2018)

Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors
por: Tusup, Marina, et al.
Publicado: (2022)

Protamine-Based Strategies for RNA Transfection
por: Jarzebska, Natalia Teresa, et al.
Publicado: (2021)

RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug
por: Jarzebska, Natalia Teresa, et al.
Publicado: (2022)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions
por: Chang, Yun-Tsan, et al.
Publicado: (2021)

Primary Localization and Tumor Thickness as Prognostic Factors of Survival in Patients with Mucosal Melanoma
por: Mehra, Tarun, et al.
Publicado: (2014)

Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
por: Mangana, Joanna, et al.
Publicado: (2017)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation
por: Saulite, Ieva, et al.
Publicado: (2020)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Long–Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T–Cell Lymphoma; Results From a Single Institution Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2020)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2017)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Publisher Correction: The low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
por: Restivo, Gaetana, et al.
Publicado: (2018)

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases
por: Zila, Nina, et al.
Publicado: (2018)

Charting DENR-dependent translation reinitiation uncovers predictive uORF features and links to circadian timekeeping via Clock
por: Castelo-Szekely, Violeta, et al.
Publicado: (2019)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome
por: Iselin, Christoph, et al.
Publicado: (2021)

Who’s Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2021)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas
por: Czyż, Małgorzata, et al.
Publicado: (2016)

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
por: Raaijmakers, Marieke I. G., et al.
Publicado: (2016)

Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018)

REDIdb: the RNA editing database
por: Picardi, Ernesto, et al.
Publicado: (2007)

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
por: Hanfstingl, Kathrin, et al.
Publicado: (2018)

Detection of A-to-I RNA Editing in SARS-COV-2
por: Picardi, Ernesto, et al.
Publicado: (2021)

Morpho-Molecular Assessment Indicates New Prognostic Aspects and Personalized Therapeutic Options in Sinonasal Melanoma
por: Freiberger, Sandra N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_62anvu3pniqkqgbtffucmua2fj